세포치료 시장 규모, 점유율, 성장, 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of cell therapy Market

The global cell therapy market is experiencing rapid growth, driven by technological advancements, increasing adoption of advanced cellular therapies, and rising demand for treatments targeting oncology and rare diseases. The market was valued at USD 8.88 billion in 2025, projected to grow to USD 12.34 billion in 2026, and is expected to reach USD 190.36 billion by 2034, reflecting a robust CAGR of 40.78% during the forecast period.

Cell therapy involves the administration of live cells, either autologous or allogeneic, into patients to treat or prevent diseases. These therapies include genetically engineered T-cells, natural killer cells, and induced pluripotent stem cell (iPSC)-derived therapies that restore normal cellular function, eliminate diseased cells, or regenerate damaged tissues. The market is dominated by leading biopharmaceutical players including Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb, supported by strong R&D pipelines, wide product availability, and global reach.

Market Dynamics

Market Drivers

High unmet medical needs, particularly in oncology and rare genetic diseases, are a major driver. Many rare diseases, comprising approximately 95% of conditions, lack FDA-approved treatments, creating demand for personalized cell therapies. The increasing number of patients with conditions such as sickle cell disease, estimated at 7.74 million globally in 2021, further fuels the need for targeted therapies. Rapid clinical progress in CAR-T and engineered T-cell therapies, coupled with expanding approvals, is propelling market growth.

Market Restraints

Safety concerns and clinical risks, including tumorigenesis, immune rejection, graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and neurotoxicity, restrict market expansion. These risks necessitate specialized hospital infrastructure and limit adoption to certified centers. For instance, Yescarta (Gilead Sciences, Inc.) recorded grade >=3 neurotoxicity in ~32% of patients with large B-cell lymphoma.

Market Opportunities

The emergence of allogeneic cell therapies offers off-the-shelf solutions, providing scalability, lower costs, and faster treatment initiation. Technological advancements and growing investment in oncology, autoimmune, and neurological applications provide significant growth opportunities. For example, Allogene Therapeutics reported promising Phase 1 data for ALLO-316 in June 2025, targeting advanced renal cell carcinoma.

Market Challenges

The high cost of treatment remains a significant challenge. CAR-T therapies such as Yescarta cost around USD 537,592 per regimen, with additional costs for hospitalization and post-treatment care. This limits accessibility, especially in emerging economies with constrained healthcare budgets.

Market Trends

A notable trend is the expansion of cell therapy applications beyond hematology into solid tumors. Companies are developing dual- and tri-CAR T-cells to overcome antigen escape and improve efficacy in solid cancers. In February 2024, the FDA approved AMTAGVI (lifileucel) by Iovance Biotherapeutics for advanced melanoma, demonstrating regulatory support for innovative therapies in oncology.

Segmentation Analysis

By Therapy Type:

• CAR-T cell therapy dominates with 98.78% market share in 2026, driven by regulatory approvals, market adoption, and investment in clinical pipelines.
• Other therapy types include TCR-T and natural killer (NK) cell therapies.

By Product:

• Yescarta leads the market due to a large target patient base, favorable reimbursement, and global distribution through over 570 authorized treatment centers.
• Abecma is projected to grow at 14.66% CAGR during the forecast period.

By Indication:

• Oncology dominates with 100% market share in 2025, fueled by a high number of approved products, expanding clinical trials, and investment flow.
• Other indications are limited, projected at USD 0.01 billion by 2032.

By End-User:

• Hospitals & clinics dominate, holding 55.43% market share in 2026, due to specialized infrastructure and alignment with reimbursement frameworks.
• Specialty clinics are projected to grow at 42.11% CAGR.

Regional Outlook

• North America: Dominates with USD 4.22 billion in 2025 and USD 5.88 billion in 2026, driven by commercialized products, strong clinical pipelines, and investments such as USD 50 million by AstraZeneca in U.S. R&D and manufacturing facilities in 2025. The U.S. is the largest contributor with USD 5.48 billion in 2026.
• Europe: Valued at USD 2.39 billion in 2025, growing at 36.55% CAGR, with the UK and Germany contributing USD 0.53 billion and USD 0.79 billion respectively in 2026.
• Asia Pacific: Estimated at USD 1.45 billion in 2025, with key markets including Japan (USD 0.43 billion), China (USD 0.77 billion), and India (USD 0.13 billion) in 2026.
• Latin America: Valued at USD 0.48 billion in 2025, adoption limited due to infrastructure constraints.
• Middle East & Africa: GCC valued at USD 0.19 billion in 2025, showing slower growth.

Competitive Landscape

The market is semi-fragmented, with major players such as Novartis AG, Gilead Sciences, Bristol Myers Squibb, Johnson & Johnson, Iovance Biotherapeutics, Fate Therapeutics, and Adaptimmune. Strategies include R&D, collaborations, licensing, and clinical partnerships to strengthen market presence.

Key Developments:

• June 2025: EMA recommended conditional marketing authorization for Zemcelpro in the EU.
• June 2025: BMS received U.S. FDA approval for Abecma and Breyanzi CAR-T therapies.
• April 2025: Thermo Fisher launched the Advanced Therapies Collaboration Center in California.
• August 2024: FDA approved the first TCR therapy, afami-cel, for synovial sarcoma.
• April 2024: India launched NexCAR19, its first homegrown CAR-T therapy.

Conclusion

The global cell therapy market is expected to grow from USD 8.88 billion in 2025 to USD 190.36 billion by 2034, at a CAGR of 40.78%. Growth is driven by the increasing adoption of CAR-T and allogeneic therapies, rising unmet medical needs in oncology and rare diseases, expanding regulatory approvals, and strategic investments by key market players. Despite high treatment costs and safety concerns, cell therapy is poised to revolutionize personalized medicine, offering curative solutions and improving patient outcomes globally.

Segmentation By Therapy Type

• CAR-T Cell Therapy
• TCR-T Cell Therapy
• Natural Killer (NK) Cells
• Others

By Product

• Kymriah
• Yescarta
• Tecartus
• Breyanzi
• Abecma
• Carvykti
• Others

By Indication

• Oncology
• Others

By End User

• Hospitals & Clinics
• Specialty Clinics
• Others

By Geography

• North America (By Therapy Type, Product, Indication, End User, and Country)
  • U.S.
  • Canada
• Europe (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Therapy Type, Product, Indication, End User, and Country/Sub-region)
  • GCC
  • South Africa
• Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Overview: Advancements in of Cell Therapy for New Disease Indications
• 4.2. Regulatory Scenarios, By Key Countries/Regions
• 4.3. Technological Advancements in the Market
• 4.4. New Product Launches, By Key Players
• 4.5. Pipeline Analysis, By Key Companies
• 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, and Others)
• 4.7. Pricing & Reimbursement Landscape in the Market
• 4.8. Manufacturing & Supply Chain Insights
• 4.9. Investment & Funding Trends in the Market

5. Global Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 5.1.1. CAR-T Cell Therapy
  • 5.1.2. TCR-T Cell Therapy
  • 5.1.3. Natural Killer (NK) Cells
  • 5.1.4. Others
• 5.2. Market Analysis, Insights and Forecast - By Product
  • 5.2.1. Kymriah
  • 5.2.2. Yescarta
  • 5.2.3. Tecartus
  • 5.2.4. Breyanzi
  • 5.2.5. Abecma
  • 5.2.6. Carvykti
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Indication
  • 5.3.1. Oncology
  • 5.3.2. Others
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals & Clinics
  • 5.4.2. Specialty Clinics
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 6.1.1. CAR-T Cell Therapy
  • 6.1.2. TCR-T Cell Therapy
  • 6.1.3. Natural Killer (NK) Cells
  • 6.1.4. Others
• 6.2. Market Analysis, Insights and Forecast - By Product
  • 6.2.1. Kymriah
  • 6.2.2. Yescarta
  • 6.2.3. Tecartus
  • 6.2.4. Breyanzi
  • 6.2.5. Abecma
  • 6.2.6. Carvykti
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Indication
  • 6.3.1. Oncology
  • 6.3.2. Others
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals & Clinics
  • 6.4.2. Specialty Clinics
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 7.1.1. CAR-T Cell Therapy
  • 7.1.2. TCR-T Cell Therapy
  • 7.1.3. Natural Killer (NK) Cells
  • 7.1.4. Others
• 7.2. Market Analysis, Insights and Forecast - By Product
  • 7.2.1. Kymriah
  • 7.2.2. Yescarta
  • 7.2.3. Tecartus
  • 7.2.4. Breyanzi
  • 7.2.5. Abecma
  • 7.2.6. Carvykti
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Indication
  • 7.3.1. Oncology
  • 7.3.2. Others
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals & Clinics
  • 7.4.2. Specialty Clinics
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. Germany
  • 7.5.2. U.K.
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 8.1.1. CAR-T Cell Therapy
  • 8.1.2. TCR-T Cell Therapy
  • 8.1.3. Natural Killer (NK) Cells
  • 8.1.4. Others
• 8.2. Market Analysis, Insights and Forecast - By Product
  • 8.2.1. Kymriah
  • 8.2.2. Yescarta
  • 8.2.3. Tecartus
  • 8.2.4. Breyanzi
  • 8.2.5. Abecma
  • 8.2.6. Carvykti
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Indication
  • 8.3.1. Oncology
  • 8.3.2. Others
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals & Clinics
  • 8.4.2. Specialty Clinics
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 9.1.1. CAR-T Cell Therapy
  • 9.1.2. TCR-T Cell Therapy
  • 9.1.3. Natural Killer (NK) Cells
  • 9.1.4. Others
• 9.2. Market Analysis, Insights and Forecast - By Product
  • 9.2.1. Kymriah
  • 9.2.2. Yescarta
  • 9.2.3. Tecartus
  • 9.2.4. Breyanzi
  • 9.2.5. Abecma
  • 9.2.6. Carvykti
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Indication
  • 9.3.1. Oncology
  • 9.3.2. Others
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals & Clinics
  • 9.4.2. Specialty Clinics
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Cell Therapy Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Therapy Type
  • 10.1.1. CAR-T Cell Therapy
  • 10.1.2. TCR-T Cell Therapy
  • 10.1.3. Natural Killer (NK) Cells
  • 10.1.4. Others
• 10.2. Market Analysis, Insights and Forecast - By Product
  • 10.2.1. Kymriah
  • 10.2.2. Yescarta
  • 10.2.3. Tecartus
  • 10.2.4. Breyanzi
  • 10.2.5. Abecma
  • 10.2.6. Carvykti
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Indication
  • 10.3.1. Oncology
  • 10.3.2. Others
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals & Clinics
  • 10.4.2. Specialty Clinics
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
  • 11.2.1. Novartis AG
  • 11.2.2. Gilead Sciences, Inc.
  • 11.2.3. Bristol Myers Squibb Company
  • 11.2.4. Johnson & Johnson
  • 11.2.5. Vertex Pharmaceuticals Incorporated
  • 11.2.6. Bayer AG
  • 11.2.7. Adaptimmune
  • 11.2.8. IOVANCE Biotherapeutics, Inc.
  • 11.2.9. F. Hoffmann-La Roche Ltd
  • 11.2.10. Fate Therapeutics